The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Open accessAbstract
BACKGROUND: There is evidence that medications or vitamins that increase the levels of brain catecholamines and protect against oxidative damage may reduce the neuronal damage and slow the progression of Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled, randomized, multicenter trial in patients with Alzheimer's disease of moderate severity. A total of 341 patients received the selective monoamine oxidase inhibitor selegiline (10 mg a day), alpha-tocopherol (vitamin E, 2000 IU a day), both selegiline and alpha-tocopherol, or placebo for two years. The primary outcome was the time to the occurrence of any of the following: death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia (defined as a Clinical Dementia Rating of 3). RESULTS: Despite random assignment, the baseline score on the Mini-Mental State Examination was higher in the placebo group than in the other three groups, and this variable was highly predictive of the primary outcome (P<0.001). In the unadjusted analyses, there was no statistically significant difference in the outcomes among the four groups. In analyses that included the base-line score on the Mini-Mental State Examination as a covariate, there were significant delays in the time to the primary outcome for the patients treated with selegiline (median time, 655 days; P=0.012), alpha-tocopherol (670 days, P=0.001) or combination therapy (585 days, P=0.049), as compared with the placebo group (440 days). CONCLUSIONS: In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“To date, none of the tested compounds have proven effective (Sano et al., 1997; Petersen et al., 2005; Pham and Plakogiannis, 2005; DeKosky et al., 2008).”
From The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease (2011) · cites this paper as Sano et al., 1997
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following a report of success of high-dose vitamin E in keeping late-stage AD patients out of long-term care facilities longer than patients on a placebo81, other studies with vitamin E have been less impressive70,78,80.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [81]
Experimental — accuracy not yet measuredIn the citing paper
“there were no concerning safely signals or increased mortality with high-dose vitamin E. 127,128”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [127]
In the citing paper
“high-dose vitamin E (1000 IU twice daily was the regimen tested) may be considered based on results of 2 RCTs that supported approximately 20% lower rate of ADL decline over approximately 2 to 3 years; there were no concerning safely signals or increased mortality with high-dose vitamin E. 127,128”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
Pryor, W. A. (1976) · Cited by 1,876
Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.
Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., & Markesbery, W. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10540 · Cited by 1,296
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,222
A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,000
The Free Radical Theory of Aging
Harman, D. (2003) · Antioxidants and Redox Signaling · doi:10.1089/152308603770310202 · Cited by 935
Research works printed but not linked: 1
- Holm S, 1979, Scand J Stat, 6, 65
Cited by
Sorted by citations
Items 201–300 of 1,005
Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment
Mangialasche, F., Polidori, M. C., Monastero, R., Ercolani, S., Camarda, C., Cecchetti, R., & Mecocci, P. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.04.002 · Cited by 250
Zinc takes the center stage: its paradoxical role in Alzheimer’s disease
Cuajungco, M. P., & Faget, K. Y. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00219-9 · Cited by 245
Schedin‐Weiss, S., Inoue, M., Hromádková, L., Teranishi, Y., Yamamoto, N. G., Wiehager, B., Bogdanović, N., Winblad, B. G., Matton, A., Frykman, S., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0279-1 · Cited by 243
Rivastigmine, a New‐Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease
Jann, M. W. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.1.1.34664 · Cited by 241
Andrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. D. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092313 · Cited by 240
Controlled trial of N-acetylcysteine for patients with probable Alzheimer’s disease
Adair, J. C., Knoefel, J. E., & Morgan, N. (2001) · Neurology · doi:10.1212/wnl.57.8.1515 · Cited by 240
Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics
Masters, C. L., Cappai, R., Barnham, K. J., & Villemagne, V. L. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03989.x · Cited by 242
The role of diet in cognitive decline
Solfrizzi, V., Panza, F., & Capurso, A. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0766-8 · Cited by 240
Yatin, S. M., Varadarajan, S., & Butterfield, D. A. (2000) · Journal of Alzheimer s Disease · doi:10.3233/jad-2000-2212 · Cited by 241
Mitochondrial dysfunction: A potential link between neuroinflammation and neurodegeneration?
Witte, M. E., Geurts, J. J. G., de Vries, H. E., van der Valk, P., & van Horssen, J. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.05.014 · Cited by 239
Vascular Basis of Alzheimer's Pathogenesis
de la Torre, J. C. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04817.x · Cited by 239
The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease.
Wilkinson, B. L., & Landreth, G. E. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-30 · Cited by 239
Antioxidants in Central Nervous System Diseases: Preclinical Promise and Translational Challenges
Kamat, C. D., Gadal, S., Mhatre, M., Williamson, K. S., Pye, Q. N., & Hensley, K. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15314 · Cited by 238
Elevation of serum copper levels in Alzheimer’s disease
Squitti, R., Lupoi, D., Pasqualetti, P., Forno, G. D., Vernieri, F., Chiovenda, P., Rossi, L. C., Cortesi, M., Cassetta, E., & Rossini, P. M. (2002) · Neurology · doi:10.1212/wnl.59.8.1153 · Cited by 237
Silverman, D. H. S. (2004) · PubMed · Cited by 235
Perkins, A. J., Hendrie, H. C., Callahan, C. M., Gao, S., Unverzagt, F. W., Xu, Y., Hall, K. S., & Hui, S. L. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009915 · Cited by 234
Neurobehavioral aspects of antioxidants in aging
Cantuti‐Castelvetri, I., Shukitt‐Hale, B., & Joseph, J. A. (2000) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(00)00008-3 · Cited by 233
Bi, D., Wen, L., Wu, Z., & Shen, Y. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12088 · Cited by 232
NMDA receptor function, memory, and brain aging
Newcomer, J. W., Farber, N. B., & Olney, J. W. (2000) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2000.2.3/jnewcomer · Cited by 232
Laurin, D. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh124 · Cited by 231
Stackman, R. W., Eckenstein, F., Frei, B., Kulhanek, D., Nowlin, J., & Quinn, J. F. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00399-6 · Cited by 230
Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease
Mecocci, P. (2002) · Archives of Neurology · doi:10.1001/archneur.59.5.794 · Cited by 229
The Free Radical Theory of Aging Revisited: The Cell Signaling Disruption Theory of Aging
Viña, J., Borrás, C., Abdelaziz, K. M., Garcia-Valles, R., & Gómez‐Cabrera, M. C. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.5111 · Cited by 229
Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
Cummings, J. L., Schneider, E., Tariot, P. N., & Graham, S. M. (2006) · Neurology · doi:10.1212/01.wnl.0000223333.42368.f1 · Cited by 227
Effective Pharmacologic Management of Alzheimer’s Disease
Farlow, M. R., & Cummings, J. L. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.08.036 · Cited by 227
Chronic Divalproex Sodium to Attenuate Agitation and Clinical Progression of Alzheimer Disease
Tariot, P. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.72 · Cited by 227
A Randomized Trial of Vitamin E Supplementation and Cognitive Function in Women
Kang, J. H. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.22.2462 · Cited by 227
MAO-inhibitors in Parkinson's Disease
Riederer, P. F., & Laux, G. (2011) · Experimental Neurobiology · doi:10.5607/en.2011.20.1.1 · Cited by 227
Pharmacologic treatments of dementia
Bonner, L. T., & Peskind, E. R. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00007-x · Cited by 226
Lloret, A., Badía, M.-C., Mora, N. J., Pallardó, F. V., Alonso, M.-D., & Viña, J. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1033 · Cited by 225
Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists
Anthony, J. C., Breitner, J. C. S., Zandi, P. P., Meyer, M. R., Jurasova, I., Norton, M. C., & Stone, S. V. (2000) · Neurology · doi:10.1212/wnl.54.11.2066 · Cited by 222
Neuronal Apoptosis in Neurodegeneration
Okouchi, M., Ekshyyan, O. Y., Maracine, M., & Aw, T. Y. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1511 · Cited by 222
Milgram, N. W., Head, E., Zicker, S. C., Ikeda-Douglas, C. J., Murphey, H. L., Muggenburg, B. A., Siwak, C. T., Tapp, D., & Cotman, C. W. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.014 · Cited by 218
Self-citationMetal Chelation as a Potential Therapy for Alzheimer's Disease
Cuajungco, M. P., Faget, K. Y., Huang, X., Tanzi, R. E., & Bush, A. I. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06938.x · Cited by 220
The Role of Iron in Neurodegeneration: Prospects for Pharmacotherapy of Parkinson??s Disease
Jellinger, K. A. (1999) · Drugs & Aging · doi:10.2165/00002512-199914020-00004 · Cited by 218
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Park, J.-H., Ju, Y. H., Choi, J. W., Song, H. J., Jang, B. K., Woo, J., Chun, H., Kim, H. J., Shin, S. J., Yarishkin, O., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav0316 · Cited by 216
High-dose antioxidant supplements and cognitive function in community-dwelling elderly women
Grodstein, F., Chen, J., & Willett, W. C. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.4.975 · Cited by 214
Diet, cognition, and alzheimer’s disease: food for thought
Otaegui-Arrazola, A., Amiano, P., Elbusto, A., Urdaneta, E., & Martínez-Lage, P. (2014) · European Journal of Nutrition · doi:10.1007/s00394-013-0561-3 · Cited by 214
Gamoh, S., Hashimoto, M., Hossain, S., & Masumura, S. (2001) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2001.03437.x · Cited by 213
Nutrition Interventions in Aging and Age‐Associated Disease
Meydani, M. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb05652.x · Cited by 213
Amyloid β-protein toxicity and oxidative stress in Alzheimer's disease
Behl, C. (1997) · Cell and Tissue Research · doi:10.1007/s004410050955 · Cited by 212
Role of p38/MAPKs in Alzheimer's Disease: Implications for Amyloid Beta Toxicity Targeted Therapy
Kheiri, G., Dolatshahi, M., Rahmani, F., & Rezaei, N. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0008 · Cited by 211
Vitamin A and Vitamin E: Will the Real Antioxidant Please Stand Up?
Blaner, W. S., Shmarakov, I. O., & Traber, M. G. (2021) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082018-124228 · Cited by 211
Navarro, A., Gómez, C., Sánchez-Pino, M.-J., González, H., Bández, M. J., Boveris, A. D., & Boveris, A. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00834.2004 · Cited by 211
Vitamin E and All-Cause Mortality: A Meta-Analysis
L. Abner, E., A. Schmitt, F., S. Mendiondo, M., L. Marcum, J., & J. Kryscio, R. (2011) · Current Aging Sciencee · doi:10.2174/1874609811104020158 · Cited by 209
Alzheimer Disease: Mechanistic Understanding Predicts Novel Therapies
Selkoe, D. J. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-8-200404200-00047 · Cited by 208
Schneider, L. S. S., Tariot, P. N., Lyketsos, C. G., Dagerman, K., Davis, K. L., Thomas, S., Hsiao, J., Jeste, D. V., Katz, I. R., Olin, J. T., et al. (2001) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200111000-00004 · Cited by 208
Self-citationCopernicus revisited: amyloid beta in Alzheimer's disease
Josepha, J. A. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00211-6 · Cited by 206
Hoofnagle, J. H., Natta, M. L. V., Kleiner, D. E., Clark, J. M., Kowdley, K. V., Loomba, R. S., Neuschwander‐Tetri, B. A., Sanyal, A. J., & Tonascia, J. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12352 · Cited by 205
(1999) · Europe PMC (PubMed Central) · Cited by 205
Monoamine oxidase-B inhibitors in the treatment of Alzheimers disease
Thomas, T. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00100-7 · Cited by 204
Behl, C., & Moosmann, B. (2002) · Biological Chemistry · doi:10.1515/bc.2002.053 · Cited by 203
Grill, J. D., & Karlawish, J. H. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt58 · Cited by 203
Increased lipoprotein oxidation in alzheimer’s disease
Schippling, S., Kontush, A., Arlt, S., Buhmann, C., Stürenburg, H.-J., Mann, U. M., Müller‐Thomsen, T., & Beisiegel†, U. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00247-6 · Cited by 202
Apoptotic Pathways and Alzheimer’s Disease: Probing Therapeutic Potential
Sharma, V., Singh, T. G., Singh, S., Garg, N., & Dhiman, S. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03418-7 · Cited by 201
Cognitive and Behavioral Neurology
Finger, E. C., & Daffner, K. R. (2011) · Springer eBooks · doi:10.1007/978-0-387-88555-1_8 · Cited by 201
The influence of common free radicals and antioxidants on development of Alzheimer’s Disease
Wojtunik‐Kulesza, K. A., Oniszczuk, A., Oniszczuk, T., & Waksmundzka‐Hajnos, M. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.12.024 · Cited by 200
“Brain-specific” nutrients: a memory cure?
McDaniel, M. A., Maier, S. F., & Einstein, G. O. (2003) · Nutrition · doi:10.1016/s0899-9007(03)00024-8 · Cited by 200
The ability of persons with Alzheimer disease (AD) to make a decision about taking an AD treatment
Karlawish, J. H., Casarett, D., James, B. D., Xie, S. X., & Kim, S. Y. H. (2005) · Neurology · doi:10.1212/01.wnl.0000160000.01742.9d · Cited by 199
Liposome delivery systems for the treatment of Alzheimer’s disease
Ross, C., Taylor, M., Fullwood, N., & Allsop, D. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s183117 · Cited by 198
Guo, Q., Sebastian, L., Sopher, B. L., Miller, M. W., Ware, C. B., Martin, G. M., & Mattson, M. P. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721019.x · Cited by 197
Cotman, C. W., & Head, E. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15413 · Cited by 197
Self-citationAntioxidant strategies for Alzheimer's disease
Grundman, M., & Delaney, P. (2002) · Proceedings of The Nutrition Society · doi:10.1079/pns2002146 · Cited by 197
Self-citationApoptosis and Alzheimer's disease
Behl, C. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070021 · Cited by 196
Harrison, F. E. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111853 · Cited by 195
Roy, R. G., Mandal, P. K., & Maroon, J. C. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00486 · Cited by 194
Alzoubi, K. H., Khabour, O. F., Rashid, B. A., Damaj, M. I., & Salah, H. A. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.09.017 · Cited by 194
Kukull, W. A., & Ganguli, M. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70233-4 · Cited by 194
Anderson‐Hanley, C., Barcelos, N. M., Zimmerman, E. A., Gillen, R. W., Dunnam, M., Cohen, B. D., Yerokhin, V., Miller, K. E., Hayes, D. J., Arciero, P. J., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00076 · Cited by 194
Animal models of Alzheimer's disease and evaluation of anti-dementia drugs
Yamada, K., & Nabeshima, T. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00081-4 · Cited by 192
Graf, M., Ecker, D., Horowski, R., Krämer, B., Riederer, P. F., Gerlach, M., Hager, C., Ludolph, A. C., Krämer, B., Ecker, D., et al. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0220-1 · Cited by 192
Barberger‐Gateau, P., Fabrigoule, C., Helmer, C., Rouch, I., & Dartigues, J. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb07239.x · Cited by 190
Alpha-lipoic acid as a new treatment option for Azheimer type dementia
Hager, K., Marahrens, A., Kenklies, M., Riederer, P., & Münch, G. (2001) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(01)00104-2 · Cited by 188
Farooqui, A. A., Ong, W., & Horrocks, L. A. (2004) · Neurochemical Research · doi:10.1007/s11064-004-6871-3 · Cited by 187
Levey, A. I., Lah, J. J., Goldstein, F. C., Steenland, K., & Bliwise, D. L. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.07.006 · Cited by 187
Ono, K., Hamaguchi, T., Naiki, H., & Yamada, M. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.002 · Cited by 186
Antioxidants in Alzheimer’s Disease: Current Therapeutic Significance and Future Prospects
Pritam, P., Deka, R., Bhardwaj, A., Srivastava, R., Kumar, D., Jha, A. K., Jha, N. K., Villa, C., & Jha, S. K. (2022) · Biology · doi:10.3390/biology11020212 · Cited by 188
Intake of α-tocopherol is limited among US adults
Maras, J. E., Bermúdez, O. I., Qiao, N., Bakun, P. J., Boody-Alter, E. L., & Tucker, K. L. (2004) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2004.01.004 · Cited by 186
Microglia as a Potential Bridge between the Amyloid β‐Peptide and Tau
Kitazawa, M., Yamasaki, T. R., & LaFerla, F. M. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.006 · Cited by 187
Mild cognitive impairment clinical trials
Petersen, R. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1155 · Cited by 185
Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease
Perry, G. L., Castellani, R. J., Hirai, K., & Smith, M. A. (1998) · Journal of Alzheimer s Disease · doi:10.3233/jad-1998-1103 · Cited by 184
Increased basal ganglia iron levels in Huntington disease
Bartzokis, G., Cummings, J., Perlman, S., Hance, D. B., & Mintz, J. (1999) · Archives of Neurology · doi:10.1001/archneur.56.5.569 · Cited by 183
Bjelakovic, G., Nikolova, D., & Gluud, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074558 · Cited by 183
Disease progression meta‐analysis model in Alzheimer's disease
Ito, K., Ahadieh, S., Corrigan, B., French, J. L., Fullerton, T., Tensfeldt, T. G., & Alzheimer's Disease Working Group (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.665 · Cited by 183
NF-κB as a therapeutic target in neurodegenerative diseases
Camandola, S., & Mattson, M. P. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.123 · Cited by 184
Combination Therapy in Alzheimer???s Disease: A Review of Current Evidence
Schmitt, B., Bernhardt, T., Moeller, H.-J., Heuser, I., & Fr??lich, L. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00001 · Cited by 182
Reactive oxygen species: the unavoidable environmental insult?
Gracy, R. W., Talent, J. M., Kong, Y., & Conrad, C. C. (1999) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s1383-5742(99)00027-7 · Cited by 182
Kontush, A. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00688-8 · Cited by 178
Current approaches in the treatment of Alzheimer's disease
Shah, R. S., Lee, H., Zhu, X., Perry, G. L., Smith, M. A., & Castellani, R. J. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.02.005 · Cited by 178
Bairati, I., Meyer, F., Jobin, É., Gélinas, M., Fortin, A., Nabid, A., Brochet, F., & Têtu, B. (2006) · International Journal of Cancer · doi:10.1002/ijc.22042 · Cited by 177
Vitamin C and Vitamin E for Alzheimer's Disease
Boothby, L. A., & Doering, P. L. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e495 · Cited by 176
Calabrese, V., Scapagnini, G., Colombrita, C., Ravagna, A., Pennisi, G., Stella, A. M. G., Galli, F., & Butterfield, D. A. (2003) · Amino Acids · doi:10.1007/s00726-003-0048-2 · Cited by 175
Guidelines for managing Alzheimer's disease: Part II. Treatment.
Cummings, J. L., Frank, J. C., Cherry, D., Kohatsu, N. D., Kemp, B. J., Hewett, L., & Mittman, B. S. (2002) · PubMed · Cited by 175
NEUROBEHAVIORAL AND NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE
Chung, J. A., & Cummings, J. L. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70228-0 · Cited by 174
Effects of Vitamin E on Cognitive Performance during Ageing and in Alzheimer’s Disease
Fata, G. L., Weber, P., & Mohajeri, M. H. (2014) · Nutrients · doi:10.3390/nu6125453 · Cited by 174
McLellan, M. E., Kajdasz, S. T., Hyman, B. T., & Bacskai, B. J. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02212.2003 · Cited by 174
Micronutrient Deficiencies: A Major Cause of DNA Damage
Ames, B. N. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb08727.x · Cited by 173
Vitamin E and Neurodegenerative Disorders Associated with Oxidative Stress
Butterfield, D. A., Castegna, A., Drake, J., Scapagnini, G., & Calabrese, V. (2002) · Nutritional Neuroscience · doi:10.1080/10284150290028954 · Cited by 172
Rival, T., Page, R. M., Chandraratna, D. S., Sendall, T. J., Ryder, E. J., Liu, B., Lewis, H. D., Rosahl, T. W., Hider, R. C., Camargo, L. M., et al. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06701.x · Cited by 171
Metadata
- Authors
- Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., Schneider, L. S., & Thal, L. J.
- Affiliations
- University of California San Diego (US)
- Harvard University (US)
- University of California, Irvine (US)
- University of South Florida (US)
- University of Southern California (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-04-24
- Volume
- 336
- Issue
- 17
- Pages
- 1216-1222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2326200998
- Cited by
- 2,380
- References
- 36
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 39 · 2023: 39 · 2022: 41 · 2021: 38 · 2020: 44 · 2019: 43 · 2018: 44 · 2017: 47 · 2016: 55 · 2015: 54 · 2014: 72 · 2013: 62 · 2012: 82
- FWCI
- 118.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U01‐AG10483, U01AG010483, U19AG010483)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, selegiline, alpha-tocopherol, vitamin E, monoamine oxidase inhibitors, combination therapy, disease progression, dementia, activities of daily living, Mini-Mental State Examination, oxidative stress, catecholamines
- MeSH terms
- Activities of Daily Living, Aged, Alzheimer Disease, Cognition, Double-Blind Method, Drug Combinations, Female, Humans, Institutionalization, Male, Mental Status Schedule, Monoamine Oxidase Inhibitors, Selegiline, Vitamin E, Proportional Hazards Models, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
